1. Home page
  2. Search

Single-agent Ibrutinib is efficacious and well tolerated in Rituximab-refractory patients with Waldenstrom's Macroglobulinemia (WM): Initial results from an international, multicenter, open-label phase 3 substudy (INNOVATE (TM))

This item is provided by the institution :
/aggregator-openarchives/portal/institutions/uoa   

Repository :
Pergamos Digital Library   

see the original item page
in the repository's web site and access all digital files if the item*



Single-agent Ibrutinib is efficacious and well tolerated in Rituximab-refractory patients with Waldenstrom's Macroglobulinemia (WM): Initial results from an international, multicenter, open-label phase 3 substudy (INNOVATE (TM))
Buske, C Trotman, J Tedeschi, A Matous, J Macdonald, D Tam, C Toumilhac, O Ma, S Oriol, A Heffner, LT others
scientific_publication_inproceedings
Επιστημονική δημοσίευση - Ανακοίνωση Συνεδρίου (EL)
Scientific publication - Conference Paper (EN)
2016
Επιστήμες Υγείας
Επιστήμες Υγείας (EL)
Health Sciences (EN)
English
Σχολή Επιστημών Υγείας » Τμήμα Ιατρικής
https://creativecommons.org/licenses/by-nc/4.0/
University of Athens
Pergamos Digital Library
Conference Paper



*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)